University of Massachusetts Medical School Faculty Publications

Title

The state and consequences of dermatology drug prices in the United States

UMMS Affiliation

Division of Dermatology, Department of Medicine

Date

9-1-2016

Document Type

Editorial

Disciplines

Dermatology | Pharmacoeconomics and Pharmaceutical Economics

Abstract

In 2014, Medicare expenditures increased 12%, the largest increase reported since 2002, resulting in major concerns by both patients and physicians. Although costs are rising for both specialty drugs and generic medications,out-of-pocket costs, restrictive formularies,and health plan bureaucracies are limiting patients' access to necessary medications. In response, the Regulatory Policy Committee of the American Academy of Dermatology (AAD)/Association (AAD/A) convened a Task Force on Drug Pricing and Transparency. This editorial summarizes the issues addressed by the task force along with relevant AAD/A policy.

Rights and Permissions

Citation: J Am Acad Dermatol. 2016 Sep;75(3):603-5. doi: 10.1016/j.jaad.2016.03.053. Epub 2016 Jul 13. Link to article on publisher's site

Comments

Full author list omitted for brevity. For full list of authors see article.

Related Resources

Link to Article in PubMed

Keywords

coinsurances, drug pricing, formulary tiering, generic drugs, out-of-pocket costs, pharmacy benefit managers, prior authorizations

PubMed ID

27423978